## **Curdin Conrad**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3615364/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis. Journal of Dermatological Treatment, 2022, 33, 1652-1660.	2.2	20
2	Papillonâ€Lefevre syndrome treated by acitretin: case report and cytokine profile. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	4
3	Interleukin-17E, inducible nitric oxide synthase and arginase1 as new biomarkers in the identification of neutrophilic dermatoses. Clinical and Experimental Dermatology, 2022, 47, 675-683.	1.3	5
4	Real-World Experience of Patient-Relevant Benefits and Treatment Satisfaction with Apremilast in Patients with Psoriasis: An Analysis of the APPRECIATE Study. Dermatology and Therapy, 2022, 12, 81-95.	3.0	6
5	Freedom from disease in psoriasis: a Delphi consensus definition by patients, nurses and physicians. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 403-412.	2.4	10
6	The cGAS–STING pathway drives type I IFN immunopathology in COVID-19. Nature, 2022, 603, 145-151.	27.8	272
7	International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis. JAMA Dermatology, 2022, 158, 561.	4.1	12
8	TYK-ing all the boxes in psoriasis. Journal of Allergy and Clinical Immunology, 2022, 149, 1936-1939.	2.9	3
9	Palmoplantar pustulosis and acrodermatitis continua of Hallopeau: demographic and clinical comparative study in a large multicentre cohort. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 1578-1583.	2.4	11
10	The biological basis of disease recurrence in psoriasis: a historical perspective and current models. British Journal of Dermatology, 2022, 186, 773-781.	1.5	32
11	Nail Involvement as a Predictor of Differential Treatment Effects of Secukinumab Versus Ustekinumab in Patients with Moderate to Severe Psoriasis. Dermatology and Therapy, 2022, 12, 233-241.	3.0	4
12	Requirements and expectations of highâ€quality biomarkers for atopic dermatitis and psoriasis in 2021—a twoâ€round Delphi survey among international experts. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 1467-1476.	2.4	14
13	Biomarkers of disease progression in people with psoriasis: a scoping review. British Journal of Dermatology, 2022, 187, 481-493.	1.5	22
14	Biomarkers of systemic treatment response in people with psoriasis: a scoping review. British Journal of Dermatology, 2022, 187, 494-506.	1.5	14
15	Secukinumab demonstrated sustained retention, effectiveness and safety in a realâ€world setting in patients with moderateâ€toâ€severe plaque psoriasis: longâ€term results from an interim analysis of the <scp>SERENA</scp> study. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 1796-1804.	2.4	6
16	Characteristics and outcomes of patients treated with apremilast in the real world: results from the APPRECIATE study. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 123-134.	2.4	25
17	Complementary Effects of Carbamylated and Citrullinated LL37 in Autoimmunity and Inflammation in Systemic Lupus Erythematosus. International Journal of Molecular Sciences, 2021, 22, 1650.	4.1	11
18	New Autoantibody Specificities in Systemic Sclerosis and Very Early Systemic Sclerosis. Antibodies, 2021, 10, 12.	2.5	8

#	Article	IF	CITATIONS
19	Drug Survival of IL-12/23, IL-17 and IL-23 InhibitorsÂfor Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study. American Journal of Clinical Dermatology, 2021, 22, 567-579.	6.7	65
20	Association of sex and systemic therapy treatment outcomes in psoriasis: a two ountry, multicentre, prospective, noninterventional registry study*. British Journal of Dermatology, 2021, 185, 1160-1168.	1.5	21
21	Integrated safety analysis of treatmentâ€emergent eczematous reactions in patients with moderateâ€toâ€severe psoriasis treated with ixekizumab, etanercept and ustekinumab. British Journal of Dermatology, 2021, 185, 865-867.	1.5	5
22	Topical Treatment of Psoriasis Vulgaris: The Swiss Treatment Pathway. Dermatology, 2021, 237, 166-178.	2.1	17
23	Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study. Journal of Dermatological Treatment, 2020, 31, 476-483.	2.2	23
24	The commensal skin microbiota triggers type I IFN–dependent innate repair responses in injured skin. Nature Immunology, 2020, 21, 1034-1045.	14.5	90
25	Anti-CXCL4 Antibody Reactivity Is Present in Systemic Sclerosis (SSc) and Correlates with the SSc Type I Interferon Signature. International Journal of Molecular Sciences, 2020, 21, 5102.	4.1	26
26	Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S). Dermatology and Therapy, 2020, 10, 663-670.	3.0	28
27	Integrated safety analysis: Frequency of urinary tract infections in patients with psoriasis treated with ixekizumab. Journal of the American Academy of Dermatology, 2020, 83, 261-263.	1.2	3
28	Baricitinibâ€induced paradoxical psoriasis. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e391-e393.	2.4	6
29	Efficacy and safety of <scp>TNF</scp> blockers and of ustekinumab in palmoplantar pustulosis and in acrodermatitis continua of Hallopeau. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2330-2338.	2.4	13
30	Linkage between patients' characteristics and prescribed systemic treatments for psoriasis: a semantic connectivity map analysis of the Swiss Dermatology Network for Targeted Therapies registry. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 2313-2318.	2.4	2
31	Human "T <sub>H</sub> 9―cells are a subpopulation of PPAR-γ <sup>+</sup> T <sub>H</sub> 2 cells. Science Immunology, 2019, 4, .	11.9	75
32	Secukinumab drug survival in patients with psoriasis: A multicenter, real-world, retrospective study. Journal of the American Academy of Dermatology, 2019, 81, 273-275.	1.2	39
33	IL-17E (IL-25) Enhances Innate Immune Responses during Skin Inflammation. Journal of Investigative Dermatology, 2019, 139, 1732-1742.e17.	0.7	42
34	CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AML. Blood Advances, 2019, 3, 3674-3687.	5.2	40
35	Psoriasis: from Pathogenesis to Targeted Therapies. Clinical Reviews in Allergy and Immunology, 2018, 54, 102-113.	6.5	151
36	TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis. Nature Communications, 2018, 9, 25.	12.8	194

#	Article	IF	CITATIONS
37	Diversification of human plasmacytoid predendritic cells in response to a single stimulus. Nature Immunology, 2018, 19, 63-75.	14.5	106
38	Regulatory T Cells Restrain Pathogenic T Helper Cells during Skin Inflammation. Cell Reports, 2018, 25, 3564-3572.e4.	6.4	49
39	Psoriasis: Classical vs. Paradoxical. The Yin-Yang of TNF and Type I Interferon. Frontiers in Immunology, 2018, 9, 2746.	4.8	96
40	Xenotransplantation Model of Psoriasis. Methods in Molecular Biology, 2017, 1559, 83-90.	0.9	7
41	Interleukin 23–Helper T Cell 17 Axis as a Treatment Target for Pityriasis Rubra Pilaris. JAMA Dermatology, 2017, 153, 304.	4.1	111
42	Infections Associated with Immunobiologics. , 2017, , 796-804.e2.		0
43	Psoriasis, Cutaneous Lupus Erithematosus and Immunobiology of the Skin. , 2016, , 192-203.		Ο
44	Efficacy and Survival of Systemic Psoriasis Treatments: An Analysis of the Swiss Registry SDNTT. Dermatology, 2016, 232, 640-647.	2.1	32
45	Superiority in Quality of Life Improvement of Biologics over Conventional Systemic Drugs in a Swiss Real-Life Psoriasis Registry. Dermatology, 2016, 232, 655-663.	2.1	18
46	PASS Syndrome: An IL-1-Driven Autoinflammatory Disease. Dermatology, 2016, 232, 254-258.	2.1	51
47	Targeting CD8+ T cells prevents psoriasis development. Journal of Allergy and Clinical Immunology, 2016, 138, 274-276.e6.	2.9	125
48	Swiss S1 Guidelines on the Systemic Treatment of Psoriasis Vulgaris. Dermatology, 2016, 232, 385-406.	2.1	39
49	The Dermatologists' Role in Managing Psoriatic Arthritis: Results of a Swiss Delphi Exercise Intended to Improve Collaboration with Rheumatologists. Dermatology, 2015, 230, 75-81.	2.1	13
50	TH17 cells promote microbial killing and innate immune sensing of DNA via interleukin 26. Nature Immunology, 2015, 16, 970-979.	14.5	182
51	Cationic antimicrobial peptides in psoriatic skin cooperate to break innate tolerance to selfâ€ÐNA. European Journal of Immunology, 2015, 45, 203-213.	2.9	129
52	The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. Nature Communications, 2014, 5, 5621.	12.8	427
53	Purpura of the Face and Neck: An Atypical Clinical Presentation Revealing a Hepatosplenic T Cell Lymphoma. Case Reports in Dermatology, 2014, 6, 37-42.	0.8	2
54	Plasmacytoid dendritic cells and regulatory T cells in the tumor microenvironment. Oncolmmunology, 2013, 2, e23887.	4.6	17

#	Article	IF	CITATIONS
55	Role of T-cell-mediated inflammation in psoriasis: pathogenesis and targeted therapy. Psoriasis: Targets and Therapy, 2013, , 1.	2.2	5
56	Anti-TNF Therapy in the Treatment of Psoriasis in a Patient with Acute-on-Chronic Pancreatitis. Dermatology, 2013, 227, 193-196.	2.1	9
57	Plasmacytoid Dendritic Cells Promote Immunosuppression in Ovarian Cancer via ICOS Costimulation of Foxp3+ T-Regulatory Cells. Cancer Research, 2012, 72, 5240-5249.	0.9	267
58	Type I IFNs at the Interface between Cutaneous Immunity and Epidermal Remodeling. Journal of Investigative Dermatology, 2012, 132, 1759-1762.	0.7	18
59	Neutrophils Activate Plasmacytoid Dendritic Cells by Releasing Self-DNA–Peptide Complexes in Systemic Lupus Erythematosus. Science Translational Medicine, 2011, 3, 73ra19.	12.4	1,080
60	Cutting Edge: A Critical Functional Role for IL-23 in Psoriasis. Journal of Immunology, 2010, 185, 5688-5691.	0.8	207
61	Plasmacytoid dendritic cells sense skin injury and promote wound healing through type I interferons. Journal of Experimental Medicine, 2010, 207, 2921-2930.	8.5	292
62	Trauma as Triggering Factor for Development of Melanocytic Nevi. Dermatology, 2010, 220, 291-296.	2.1	18
63	Melanoma and innate immunity – Active inflammation or just erroneous attraction?. Seminars in Cancer Biology, 2009, 19, 84-91.	9.6	35
64	Interplay between keratinocytes and immune cells—Recent insights into psoriasis pathogenesis. International Journal of Biochemistry and Cell Biology, 2009, 41, 963-968.	2.8	92
65	Plasmacytoid dendritic cells in the skin: To sense or not to sense nucleic acids. Seminars in Immunology, 2009, 21, 101-109.	5.6	56
66	The pathogenic role of tissue-resident immune cells in psoriasis. Trends in Immunology, 2007, 28, 51-57.	6.8	128
67	α1β1 integrin is crucial for accumulation of epidermal T cells and the development of psoriasis. Nature Medicine, 2007, 13, 836-842.	30.7	241
68	Animal models of psoriasis and psoriatic arthritis: An update. Current Rheumatology Reports, 2006, 8, 342-347.	4.7	17
69	Current State and Perspectives of Dendritic Cell Vaccination in Cancer Immunotherapy. Skin Pharmacology and Physiology, 2006, 19, 124-131.	2.5	16
70	Dendritic-cell-based therapeutic vaccination against cancer. Current Opinion in Immunology, 2005, 17, 163-169.	5.5	182
71	Activation of dendritic antigen-presenting cells expressing common heat shock protein receptor CD91 during induction of psoriasis British Journal of Dermatology, 2005, 152, 1211-1218.	1.5	46
72	Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nature Medicine, 2005, 11, 138-145.	30.7	356

#	Article	IF	CITATIONS
73	Pyoderma gangrenosum. JDDG - Journal of the German Society of Dermatology, 2005, 3, 334-342.	0.8	49
74	Disease-Independent Skin Recruitment and Activation of Plasmacytoid Predendritic Cells Following Imiquimod Treatment. Journal of the National Cancer Institute, 2005, 97, 1143-1153.	6.3	173
75	Plasmacytoid predendritic cells initiate psoriasis through interferon-α production. Journal of Experimental Medicine, 2005, 202, 135-143.	8.5	999
76	Psoriasis Triggered by Toll-like Receptor 7 Agonist Imiquimod in the Presence of Dermal Plasmacytoid Dendritic Cell Precursors. Archives of Dermatology, 2004, 140, 1490-5.	1.4	364
77	The IL-12 Family Member p40 Chain as a Master Switch and Novel Therapeutic Target in Psoriasis. Journal of Investigative Dermatology, 2004, 123, xiv-xv.	0.7	49
78	Spontaneous Development of Psoriasis in a New Animal Model Shows an Essential Role for Resident T Cells and Tumor Necrosis Factor-α. Journal of Experimental Medicine, 2004, 199, 731-736.	8.5	463
79	Mechanisms of psoriasis. Drug Discovery Today Disease Mechanisms, 2004, 1, 315-319.	0.8	16
80	Dendritic cell-based cancer therapy. Current Opinion in Molecular Therapeutics, 2003, 5, 405-12.	2.8	11